10-Q: Alpha Cognition Reports First Revenue Amid Rising Costs

Alpha Cognition Inc. achieved its first product and licensing revenue in Q3 2025, driven by the commercial launch of ZUNVEYL for Alzheimer's disease, despite increased operating expenses and a higher net loss.

Summary

• Generated first-time product revenue of $4,257,562 and licensing revenue of $3,169,637 for the nine months ended September 30, 2025.
• Net loss increased by 54% to $(13,813,569) for the nine months ended September 30, 2025, compared to $(8,978,129) in the prior year.
• Selling, General and Administrative (SG&A) expenses surged by 201% to $19,185,161, primarily due to the commercial launch of ZUNVEYL.
• Research and Development (R&D) expenses decreased by 55% to $1,298,223, following FDA approval of ZUNVEYL in July 2024.
• Cash and cash equivalents stood at $35,398,899 as of September 30, 2025, down from $48,546,210 at December 31, 2024.
• Successfully raised approximately $35 million gross proceeds from a public offering on October 2, 2025, and an additional $5.25 million from an over-allotment option on October 17, 2025.
• A material weakness in internal control over financial reporting was identified related to the valuation of warrant liabilities.

Sentiment

Score: 4

Explanation: The company achieved its first revenue, a major milestone, and secured a significant licensing deal. However, the substantial increase in net loss and operating expenses, coupled with a material weakness in internal controls and ongoing need for capital, indicates a challenging financial position despite commercial progress.

Positives

• Achieved first-time product revenue of $4,257,562 and licensing revenue of $3,169,637 for the nine months ended September 30, 2025, marking a significant commercial milestone.
• Secured a $3.0 million upfront payment from the CMS License Agreement for ZUNVEYL commercialization in the Asia-Pacific region, with potential for up to $41.0 million in additional milestone payments and 9% annual royalties.
• FDA approval for ZUNVEYL for mild-to-moderate Alzheimer's disease was granted on July 29, 2024, leading to its commercial launch on March 17, 2025.
• A new patent for "Coated Tablets for pH-Dependent Release of Benzgalantamine" was granted on January 25, 2025, extending the useful life of the related license to 2044 and reducing amortization expense by approximately $43,122 for the nine months ended September 30, 2025.
• ALPHA-0602 received Orphan Drug Designation for the treatment of ALS from the FDA in February 2020.
• Management believes existing cash and cash equivalents are sufficient to fund projected base operating expenses, ZUNVEYL commercialization, CMC costs, pre-clinical R&D, and ongoing operating costs and capital expenditures through at least the next 24 months.
• Net loss per share (basic and diluted) improved from $(1.51) in 2024 to $(0.86) and $(0.87) respectively in 2025, despite a higher absolute net loss, due to increased share count.

Negatives

• Net loss increased by 54% to $(13,813,569) for the nine months ended September 30, 2025, compared to $(8,978,129) for the same period in 2024.
• Total operating expenses increased by 138% to $22,162,618 for the nine months ended September 30, 2025, driven primarily by commercialization efforts.
• Selling, General and Administrative (SG&A) expenses increased by 201% or $12,804,708 for the nine months ended September 30, 2025, due to commercial operations and the ZUNVEYL launch.
• Cash used in operating activities increased by 147% to $(13,473,949) for the nine months ended September 30, 2025, indicating a higher cash burn rate.
• Cash and cash equivalents decreased from $48,546,210 at December 31, 2024, to $35,398,899 at September 30, 2025.
• A material weakness in internal control over financial reporting was identified related to the precision of review over the initial valuation and subsequent remeasurement of non-cash warrant liabilities.

Risks

• Additional financing may not be available on a timely basis or on terms acceptable to the Company, despite current liquidity projections.
• Recently announced changes to U.S. trade policy, including tariffs, could adversely affect the business, leading to inflationary pressures, lower economic growth, supply chain disruptions, and reduced customer demand.
• Failure to remediate the identified material weakness in internal control over financial reporting could result in material misstatements in consolidated financial statements and a failure to meet reporting obligations.
• The Company's operating plan may change, and available capital resources could be utilized sooner than expected.
• Raising additional capital through equity or convertible debt securities will dilute existing ownership interest.
• Debt financing and preferred equity financing may involve restrictive covenants.
• Collaborations or license agreements may require relinquishing valuable rights to technologies or future revenue streams.
• Inability to raise additional funds could lead to delays, limitations, reductions, or termination of product development or commercialization efforts, or even cessation of operations.

Future Outlook

The Company expects expenses to increase substantially with the ongoing commercialization of ZUNVEYL, potential development of additional product candidates, clinical trials, R&D, manufacturing, and public company costs. Management estimates existing cash and cash equivalents are sufficient to fund projected base operating expenses, ZUNVEYL commercialization, CMC costs, pre-clinical R&D, and ongoing operating costs and capital expenditures through at least the next 24 months. The Company plans to continue relying on debt, equity raises, and potentially non-dilutive financing options, including partnership activities, to finance operations and commercialization plans. There is a risk that additional financing may not be available on acceptable terms or at all. The Company also intends to out-license its pre-clinical Progranulin and Progranulin GEMs assets.

Management Comments

• "Management is of the opinion that it does have sufficient working capital to fully meet the Company's liabilities and commitments as outlined and planned."
• "Management is of the opinion it will need to raise additional capital to cover upcoming planned Research and Development (R&D), commercialization of ZUNVEYL and operating costs."
• "The Company reduced time in research and development after the FDA approval in July 2024."
• "Alpha Cognition has set the Wholesale Acquisition Cost (WAC) for its therapeutic product at $820 per month. This pricing reflects the company's commitment to balancing patient access with the value of innovative healthcare solutions."

Industry Context

Alpha Cognition operates in the highly competitive biopharmaceutical sector, focusing on neurodegenerative diseases like Alzheimer's, TBI, and ALS, areas with significant unmet medical needs and limited treatment options. The commercial launch of ZUNVEYL positions the company to compete with existing acetylcholinesterase inhibitor treatments, aiming to differentiate through minimal gastrointestinal side effects and binding to neuronal nicotinic receptors. The strategic focus on long-term care facilities and Medicare payors is a common approach for new drug launches in this space. The decision to out-license early-stage assets like Progranulin GEMs reflects a common industry practice for smaller biotechs to focus resources on core commercial products while seeking to monetize non-core assets. The company's reliance on external financing for R&D and commercialization is typical for a commercial-stage biotech with a newly launched product.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.

Related Party Transactions

• Mr. McFadden, CEO, has earned 65,566 bonus rights out of a potential 327,830, valued at $107,437 as of September 30, 2025.
• Ms. DAngelo has earned 29,505 bonus rights out of a potential 42,618, valued at $44,729 as of September 30, 2025.
• $659,568 is owing to directors and officers for fees and management compensation as of September 30, 2025.
• The promissory note of $911,463 owed to Neurodyn Life Sciences Inc. (NLS) was repaid during the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Experience dilution from recent and potential future capital raises. Benefit from initial revenue generation and strategic licensing deals. Face increased net losses and operating expenses. Impacted by the identified material weakness in internal controls.
• Employees: Benefit from the 2025 Stock and Incentive Plan. Increased hiring for commercial activities.
• Customers (Patients/Healthcare Providers): Access to ZUNVEYL for mild-to-moderate Alzheimer's disease. WAC set at $820/month, with out-of-pocket costs depending on insurance.
• Suppliers/Partners: CMS International Development and Management Limited is a new strategic partner for ZUNVEYL in Asia-Pacific, Australia, and New Zealand. Neurodyn Life Sciences Inc. (NLS) continues to receive royalty payments.
• Creditors: Promissory note to NLS has been repaid.

Next Steps

• Continue commercialization of ZUNVEYL in AD, focusing on long-term care facilities and Medicare payors.
• Seek to discover and develop additional product candidates.
• Conduct ongoing and planned clinical trials and preclinical studies.
• Continue R&D activities.
• Utilize third parties for ZUNVEYL manufacturing.
• Hire additional personnel and expand intellectual property.
• Remediate the material weakness in internal control over financial reporting by enhancing the system of internal controls, including those involving third-party valuation specialists.
• Evaluate the potential impact of new accounting standard ASU 2024-03 on financial statements and disclosures.
• Seek to out-license ALPHA-0602, ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEMs) assets.
• Potentially utilize the At the Market Offering Agreement to raise up to $75.0 million in common shares.

Key Dates

Recommendation

While Alpha Cognition has achieved a significant milestone with its first product and licensing revenue, demonstrating commercial progress for ZUNVEYL, the substantial increase in net loss and operating expenses indicates the high cost of market entry and commercialization. The recent capital raises provide near-term liquidity, but the ongoing need for additional funding and the identified material weakness in internal controls present notable risks. The long-term potential of ZUNVEYL and other pipeline assets is promising, but the company is in a critical, cash-intensive phase. Investors should hold to monitor the trajectory of ZUNVEYL sales, the effectiveness of commercialization efforts, the remediation of internal control weaknesses, and the company's ability to achieve profitability or significantly reduce cash burn.

Keywords

Alpha Cognition, ZUNVEYL, Alzheimer's Disease, Neurodegenerative Diseases, Biopharmaceutical, SEC Filing, 10-Q, Financial Results, Commercialization, Drug Development, Orphan Drug, ALS, mTBI, Biotech, Pharmaceutical, FDA Approval, Capital Raise, Internal Controls